Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...
An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...
The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...
Hepion Pharmaceuticals (NASDAQ:HEPA) completed patient dosing in the 75 mg cohort of its Phase 2a ‘AMBITION’ clinical trial, which is evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). In...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from a translational research study in which its lead drug candidate, CRV431, decreased formation of procoagulant platelets. The company noted that patients with...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that an independent data safety monitoring board (DSMB) approved the continuation of the company’s Phase 2a ‘AMBITION’ clinical trial to the next dose level cohort. After...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present positive findings from an expanded study of CRV431 at The Liver Meeting Digital Experience 2020 on Nov. 13. The poster presentation will review a study in which...
Hepion Pharmaceuticals (NASDAQ:HEPA) enrolled the last patient in the 75 mg cohort of its Phase 2 ‘AMBITION’ clinical trial evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to...
After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...
Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.